Clinical trial
CP-461 for the Treatment of Crohn's Disease
NCT00042055 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00042055 |
|---|---|
| Title | CP-461 for the Treatment of Crohn's Disease |
| Official title | A Phase II Pilot Study of CP-461 in the Treatment of Moderately to Severely Active Crohn's Disease |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Cell Pathways Industry OSI Pharmaceuticals |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | CP-461 |
| Enrollment | 30 |
| Start date | Jul 1, 2002 |
| Completion | Sep 1, 2003 |
| First posted | Jul 24, 2002 |
| Last update posted | Oct 17, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: